| Kevin M Curl, MD | |
|
2309 E Evesham Rd Ste 201, Voorhees, NJ 08043-1559 | |
| (856) 325-5400 | |
| (856) 325-5416 |
| Full Name | Kevin M Curl |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 13 Years |
| Location | 2309 E Evesham Rd Ste 201, Voorhees, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154611234 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virtua West Jersey Hospitals | Voorhees, NJ | Hospital |
| Virtua Our Lady Of Lourdes Hospital | Camden, NJ | Hospital |
| Virtua Memorial Hospital Of Burlington County | Mount holly, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virtua Medical Group, Pa | 9830222397 | 1226 |
News Archive
A gut hormone, ghrelin, is a key regulator of new nerve cells in the adult brain, a Swansea-led research team has discovered. It could help pave the way for new drugs to treat dementia in patients with Parkinson's Disease.
New research aims to shed light on reducing the loss of speech and language in epilepsy patients who require brain surgery to manage the condition.
Diffusion Pharmaceuticals LLC announced today that it has opened for enrollment a clinical trial testing the company's lead drug candidate trans sodium crocetinate (TSC) as a first-line treatment for newly diagnosed primary brain cancer, also known as glioblastoma or GBM.
CombiMatrix Corporation today announced that it received a written notice from The Nasdaq Stock Market (the "Notice") on November 17, 2010 indicating that the Company is not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Global Market (as set forth in Nasdaq Listing Rule 5450(b)(1)(A)) because the Company's stockholders' equity is below The Nasdaq Global Market minimum stockholders' equity listing requirement of $10,000,000.
› Verified 5 days ago
| Entity Name | Virtua Medical Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226515 PECOS PAC ID: 9830222397 Enrollment ID: O20100804000338 |
News Archive
A gut hormone, ghrelin, is a key regulator of new nerve cells in the adult brain, a Swansea-led research team has discovered. It could help pave the way for new drugs to treat dementia in patients with Parkinson's Disease.
New research aims to shed light on reducing the loss of speech and language in epilepsy patients who require brain surgery to manage the condition.
Diffusion Pharmaceuticals LLC announced today that it has opened for enrollment a clinical trial testing the company's lead drug candidate trans sodium crocetinate (TSC) as a first-line treatment for newly diagnosed primary brain cancer, also known as glioblastoma or GBM.
CombiMatrix Corporation today announced that it received a written notice from The Nasdaq Stock Market (the "Notice") on November 17, 2010 indicating that the Company is not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Global Market (as set forth in Nasdaq Listing Rule 5450(b)(1)(A)) because the Company's stockholders' equity is below The Nasdaq Global Market minimum stockholders' equity listing requirement of $10,000,000.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin M Curl, MD 301 Lippincott Dr Ste 410, Marlton, NJ 08053-4197 Ph: (856) 355-0230 | Kevin M Curl, MD 2309 E Evesham Rd Ste 201, Voorhees, NJ 08043-1559 Ph: (856) 325-5400 |
News Archive
A gut hormone, ghrelin, is a key regulator of new nerve cells in the adult brain, a Swansea-led research team has discovered. It could help pave the way for new drugs to treat dementia in patients with Parkinson's Disease.
New research aims to shed light on reducing the loss of speech and language in epilepsy patients who require brain surgery to manage the condition.
Diffusion Pharmaceuticals LLC announced today that it has opened for enrollment a clinical trial testing the company's lead drug candidate trans sodium crocetinate (TSC) as a first-line treatment for newly diagnosed primary brain cancer, also known as glioblastoma or GBM.
CombiMatrix Corporation today announced that it received a written notice from The Nasdaq Stock Market (the "Notice") on November 17, 2010 indicating that the Company is not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Global Market (as set forth in Nasdaq Listing Rule 5450(b)(1)(A)) because the Company's stockholders' equity is below The Nasdaq Global Market minimum stockholders' equity listing requirement of $10,000,000.
› Verified 5 days ago
Kumar Rajagopalan, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 900 Centennial Blvd Ste M, Voorhees, NJ 08043 Phone: 856-325-6750 Fax: 856-325-6777 | |
Amy M Evangelisto, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2301 E. Evesham Road, Bldg 800, Suite 115, Voorhees, NJ 08043 Phone: 856-424-5005 Fax: 856-424-4716 | |
Stephen M Akers, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 900 Centennial Blvd, Suite K, Voorhees, NJ 08043 Phone: 856-325-6789 | |
Jason Palermo, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2309 E Evesham Rd, Suites 201 & 202, Voorhees, NJ 08043 Phone: 856-325-5400 Fax: 856-325-5416 | |
Dr. Robert Charles Baker, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 75 Wynnewood Dr, Voorhees, NJ 08043 Phone: 609-352-2012 Fax: 856-489-1420 | |
Dr. Eduardo Francisco Enriquez, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3 Brendenwood Dr, Voorhees, NJ 08043 Phone: 856-874-0202 Fax: 856-874-0220 | |
Arielle S. Silver, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2301 E. Evesham Road, Bldg 800, Suite 115, Voorhees, NJ 08043 Phone: 856-424-5005 Fax: 856-424-4716 |